Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Announces Additional Job Cuts as Part of Restructuring

NEW YORK (GenomeWeb) – Interpace Diagnostics announced today that it has cut 18 employees as part of an ongoing effort to restructure itself into a pure-play molecular diagnostics firm.

The move, the company said, will result in about $11.5 million in annual cost savings. 

In November, Interpace — formerly known as PDI — disclosed that it was selling off its biomedical commercialization and marketing services business in order to focus on its molecular diagnostic offerings, which include the ThyGenX genetic mutation panel and its soon-to-be-launched ThyraMir microRNA expression classifier. A month later, the firm trimmed 36 staffers, primarily from its commercial services segment. 

Interpace said today it has since eliminated the additional positions, while realigning its compensation structure, consolidating job roles, eliminating certain R&D programs, and streamlining its operating systems.

"The transition process from being a combined contract sales and molecular diagnostics business to a standalone, fully integrated molecular diagnostics company is nearly complete," Interim President and CEO Jack Stover said in a statement "Our job now is to begin delivering consistent growth in our core molecular diagnostics business that we are confident is possible while continuing to focus on controlling costs."

During early morning trading on the Nasdaq, shares of Interpace were down 6 percent at $.23.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.